What question did this study set out to answer?

To explore the clinicopathologic features and treatment implications of KRAS-Q61H mutation in lung adenocarcinoma.

February 14, 2026Frontiers in OncologyOpen Access

Lung adenocarcinoma with KRAS-Q61H: clinicopathologic features, diagnostics, and the evolving treatment landscape

View Full Paper

Ask AI

Bookmark

To explore the clinicopathologic features and treatment implications of KRAS-Q61H mutation in lung adenocarcinoma.
Reviewed clinical and molecular profiles of KRAS-Q61H lung adenocarcinoma
Analyzed the activation of RAF-MEK-ERK pathway
Examined co-mutations with TP53 and their implications for genomic instability
Discussed the role of next-generation sequencing and liquid biopsies in diagnostics
KRAS-Q61H is linked to advanced-stage lung adenocarcinoma and atypical metastatic spread.
Co-mutation with TP53 increases metastatic potential and genomic instability.
Emerging therapeutic strategies are being developed targeting the MAPK pathway and other related factors.

No takes yet. Share an insight, caveat, or question.

This review highlights the aggressive nature of KRAS-Q61H lung adenocarcinoma, indicating a need for better diagnostics and therapies.

Ioannis Serafimidis (2026) studied this question.

View Full Paper

Ask AI

Bookmark